Historic Global Goods: Difference between revisions
No edit summary |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 16: | Line 16: | ||
|style="background-color:#96d68f; border-bottom:solid 5px black" | 9 | |style="background-color:#96d68f; border-bottom:solid 5px black" | 9 | ||
|style="background-color:#f7e5ab; border-bottom:solid 5px black" | 6 | |style="background-color:#f7e5ab; border-bottom:solid 5px black" | 6 | ||
|rowspan="1" style="border-bottom:solid 5px black"| N/A | |rowspan="1" style="border-bottom:solid 5px black"| N/A | ||
|- | |- | ||
| Line 163: | Line 156: | ||
|} | |} | ||
==Pharmadex== | ==Pharmadex== | ||
Latest revision as of 17:39, 15 February 2023
Maturity of Global Goods: Summary Table
This table reflects the maturity model baseline assessments and the historical reassessment of global goods funded through Digital Square. All maturity model assessments are *self-reported* by the funded organization leading the software development of the global good. For more information about global good maturity models, please contact Carl Fourie at cfourie@path.org.
| Global Good | Global Utility | Community | Software | Change | |
|---|---|---|---|---|---|
| ODK-X | Baseline (July 2021) | 7 | 9 | 6 | N/A |
| Pharmadex | Baseline (July 2021) | 8 | 10 | 7 | N/A |
| Healthsites | Baseline (March 2021) | 6 | 8 | 8 | N/A |
Maturity by Global Good
Healthsites
| Category | Update (March 2021) | |
| Global Utility | ||
|---|---|---|
| Country Utilization | Medium | |
| Country Strategy | Medium | |
| Digital Health Interventions | High | |
| Source Code Accessibility | High | |
| Funding and Revenue | Low | |
| Community | ||
| Developer, Contributor, and Implementer Community Engagement | High | |
| Community Governance | High | |
| Software Roadmap | Medium | |
| User Documentation | High | |
| Multi-lingual Support | Medium | |
| Software | ||
| Technical Documentation | Medium | |
| Software Productization | Medium | |
| Interoperability and Data Accessibility | High | |
| Security | High | |
| Scalability | High | |
ODK-X
| Category | Baseline (July 2021) | |
| Global Utility | ||
|---|---|---|
| Country Utilization | Low | |
| Country Strategy | High | |
| Digital Health Interventions | High | |
| Source Code Accessibility | High | |
| Funding and Revenue | Medium | |
| Community | ||
| Developer, Contributor, and Implementer Community Engagement | High | |
| Community Governance | High | |
| Software Roadmap | High | |
| User Documentation | High | |
| Multi-lingual Support | Medium | |
| Software | ||
| Technical Documentation | Medium | |
| Software Productization | High | |
| Interoperability and Data Accessibility | Medium | |
| Security | Medium | |
| Scalability | Medium | |
Pharmadex
| Category | Baseline (July 2021) | |
| Global Utility | ||
|---|---|---|
| Country Utilization | Medium | |
| Country Strategy | Medium | |
| Digital Health Interventions | High | |
| Source Code Accessibility | High | |
| Funding and Revenue | High | |
| Community | ||
| Developer, Contributor, and Implementer Community Engagement | High | |
| Community Governance | High | |
| Software Roadmap | High | |
| User Documentation | High | |
| Multi-lingual Support | High | |
| Software | ||
| Technical Documentation | High | |
| Software Productization | Medium | |
| Interoperability and Data Accessibility | Medium | |
| Security | High | |
| Scalability | Medium | |
